Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
Total Valuation
Mersana Therapeutics has a market cap or net worth of $40.74M. The enterprise value is $70.72M.
Market Cap$40.74M
Enterprise Value$70.72M
Share Statistics
Mersana Therapeutics has 124,631,340 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding124,631,340
Owned by Insiders17.55%
Owned by Institutions0.11%
Financial Efficiency
Mersana Therapeutics’s return on equity (ROE) is 7.28 and return on invested capital (ROIC) is -74.86%.
Return on Equity (ROE)7.28
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-74.86%
Return on Capital Employed (ROCE)-0.89
Revenue Per Employee397.03K
Profits Per Employee-678.35K
Employee Count102
Asset Turnover0.28
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Mersana Therapeutics is -2.53. Mersana Therapeutics’s PEG ratio is 0.04.
PE Ratio-2.53
PS Ratio1.31
PB Ratio-18.43
Price to Fair Value-18.43
Price to FCF-2.12
Price to Operating Cash Flow-2.13
PEG Ratio0.04
Income Statement
In the last 12 months, Mersana Therapeutics had revenue of 40.50M and earned -69.19M in profits. Earnings per share was -0.56.
Revenue40.50M
Gross Profit40.50M
Operating Income-73.34M
Pretax Income-68.77M
Net Income-69.19M
EBITDA-63.27M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was -82.34M and capital expenditures -132.00K, giving a free cash flow of -82.47M billion.
Operating Cash Flow-82.34M
Free Cash Flow-82.47M
Free Cash Flow per Share-0.66
Dividends & Yields
Mersana Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.48
52-Week Price Change-89.52%
50-Day Moving Average0.46
200-Day Moving Average1.42
Relative Strength Index (RSI)44.18
Average Volume (3m)2.91M
Important Dates
Mersana Therapeutics upcoming earnings date is May 12, 2025, TBA Not Confirmed.
Last Earnings DateMar 3, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Mersana Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of -300.75%
Current Ratio2.19
Quick Ratio2.19
Debt to Market Cap0.10
Net Debt to EBITDA1.42
Interest Coverage Ratio-18.93
Taxes
In the past 12 months, Mersana Therapeutics has paid 418.00K in taxes.
Income Tax418.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Mersana Therapeutics EV to EBITDA ratio is -1.35, with an EV/FCF ratio of -1.03.
EV to Sales2.10
EV to EBITDA-1.35
EV to Free Cash Flow-1.03
EV to Operating Cash Flow-1.03
Balance Sheet
Mersana Therapeutics has $134.62M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$106.02M billion.
Cash & Marketable Securities$134.62M
Total Debt$0.00
Net Cash-$106.02M
Net Cash Per Share-$0.85
Tangible Book Value Per Share-$0.08
Margins
Gross margin is 56.37%, with operating margin of -181.09%, and net profit margin of -170.86%.
Gross Margin56.37%
Operating Margin-181.09%
Pretax Margin-169.82%
Net Profit Margin-170.86%
EBITDA Margin-156.24%
EBIT Margin-160.26%
Analyst Forecast
The average price target for Mersana Therapeutics is $4.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.50
Price Target Upside1263.64% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast9.88%
EPS Growth Forecast62.31%